Simon Kreutzfeldt
Overview
Explore the profile of Simon Kreutzfeldt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
626
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kerle I, Gross T, Kogler A, Arnold J, Werner M, Eckardt J, et al.
NPJ Precis Oncol
. 2025 Jan;
9(1):9.
PMID: 39794422
Precision oncology offers new cancer treatment options, yet sequencing methods vary in type and scope. In this study, we compared whole-exome/whole-genome (WES/WGS) and transcriptome sequencing (TS) with broad panel sequencing...
2.
Mock A, Teleanu M, Kreutzfeldt S, Heilig C, Hullein J, Mohrmann L, et al.
NPJ Precis Oncol
. 2023 Oct;
7(1):109.
PMID: 37884744
Analysis of selected cancer genes has become an important tool in precision oncology but cannot fully capture the molecular features and, most importantly, vulnerabilities of individual tumors. Observational and interventional...
3.
Wurm A, Brilloff S, Kolovich S, Schafer S, Rahimian E, Kufrin V, et al.
Cell Rep Med
. 2023 Sep;
4(10):101200.
PMID: 37734378
Targeted therapies are effective in treating cancer, but success depends on identifying cancer vulnerabilities. In our study, we utilize small RNA sequencing to examine the impact of pathway activation on...
4.
Kreutzfeldt S, Horak P, Hubschmann D, Knurr A, Frohling S
JCO Clin Cancer Inform
. 2023 Mar;
7:e2200147.
PMID: 36888935
No abstract available.
5.
Morfouace M, Horak P, Kreutzfeldt S, Stevovic A, de Rojas T, Denisova E, et al.
Eur J Cancer
. 2022 Dec;
178:216-226.
PMID: 36470093
Background: Adolescent and young adult (AYA) patients with cancer are poorly recruited to molecularly targeted trials and have not witnessed the advances in cancer treatment and survival seen in other...
6.
Horak P, Griffith M, Danos A, Pitel B, Madhavan S, Liu X, et al.
Genet Med
. 2022 Sep;
24(9):1991.
PMID: 36063163
No abstract available.
7.
Hoffmeister-Wittmann P, Mock A, Nichetti F, Korell F, Heilig C, Scherr A, et al.
Liver Int
. 2022 Aug;
42(12):2855-2870.
PMID: 35983950
Intrahepatic, perihilar, and distal cholangiocarcinoma (iCCA, pCCA, dCCA) are highly malignant tumours with increasing mortality rates due to therapy resistances. Among the mechanisms mediating resistance, overexpression of anti-apoptotic Bcl-2 proteins...
8.
Mohrmann L, Werner M, Oles M, Mock A, Uhrig S, Jahn A, et al.
Nat Commun
. 2022 Aug;
13(1):4485.
PMID: 35918329
The benefit of molecularly-informed therapies in cancer of unknown primary (CUP) is unclear. Here, we use comprehensive molecular characterization by whole genome/exome, transcriptome and methylome analysis in 70 CUP patients...
9.
Heilig C, Lassmann A, Mughal S, Mock A, Pirmann S, Teleanu V, et al.
Eur J Cancer
. 2022 Jun;
172:107-118.
PMID: 35763870
Background: The multi-receptor tyrosine kinase inhibitor pazopanib is approved for the treatment of advanced soft-tissue sarcoma and has also shown activity in other sarcoma subtypes. However, its clinical efficacy is...
10.
Lier A, Penzel R, Heining C, Horak P, Frohlich M, Uhrig S, et al.
JCO Precis Oncol
. 2022 Feb;
2:1-13.
PMID: 35135162
Purpose: Rapidly evolving genomics technologies, in particular comprehensive next-generation sequencing (NGS), have led to exponential growth in the understanding of cancer biology, shifting oncology toward personalized treatment strategies. However, comprehensive...